MX2022000521A - Compuestos n-sustituidos-3,4-(5-anillo fusionado)-5-fenil-pirrolid in-2-ona como inhibidores de la enzima isoqc y/o qc. - Google Patents
Compuestos n-sustituidos-3,4-(5-anillo fusionado)-5-fenil-pirrolid in-2-ona como inhibidores de la enzima isoqc y/o qc.Info
- Publication number
- MX2022000521A MX2022000521A MX2022000521A MX2022000521A MX2022000521A MX 2022000521 A MX2022000521 A MX 2022000521A MX 2022000521 A MX2022000521 A MX 2022000521A MX 2022000521 A MX2022000521 A MX 2022000521A MX 2022000521 A MX2022000521 A MX 2022000521A
- Authority
- MX
- Mexico
- Prior art keywords
- enzyme
- compounds
- isoqc
- fused
- phenyl
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title abstract 6
- 108090000790 Enzymes Proteins 0.000 title abstract 6
- 239000003112 inhibitor Substances 0.000 title 1
- 102100029865 Glutaminyl-peptide cyclotransferase-like protein Human genes 0.000 abstract 5
- 101710090339 Glutaminyl-peptide cyclotransferase-like protein Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101000585397 Homo sapiens Glutaminyl-peptide cyclotransferase-like protein Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 abstract 1
- 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19185997 | 2019-07-12 | ||
| PCT/EP2020/069630 WO2021009068A1 (en) | 2019-07-12 | 2020-07-10 | N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000521A true MX2022000521A (es) | 2022-06-14 |
Family
ID=67262155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000521A MX2022000521A (es) | 2019-07-12 | 2020-07-10 | Compuestos n-sustituidos-3,4-(5-anillo fusionado)-5-fenil-pirrolid in-2-ona como inhibidores de la enzima isoqc y/o qc. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230077723A1 (enExample) |
| EP (1) | EP3997091A1 (enExample) |
| JP (1) | JP2022542540A (enExample) |
| KR (1) | KR20220054293A (enExample) |
| CN (1) | CN114466849B (enExample) |
| AU (1) | AU2020312647A1 (enExample) |
| BR (1) | BR112022000505A8 (enExample) |
| CA (1) | CA3147154A1 (enExample) |
| IL (1) | IL289784A (enExample) |
| MX (1) | MX2022000521A (enExample) |
| PH (1) | PH12022550079A1 (enExample) |
| WO (1) | WO2021009068A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3226468A1 (en) | 2021-08-02 | 2023-02-09 | Andrew Edmunds | Microbiocidal pyrazole derivatives |
| AU2022203580A1 (en) * | 2021-09-17 | 2023-04-06 | Academia Sinica | Methods of Increasing Cell Phagocytosis |
| JP2024546927A (ja) | 2021-12-17 | 2024-12-26 | シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト | 殺微生物性ピラゾール誘導体 |
| TW202430514A (zh) | 2022-09-30 | 2024-08-01 | 瑞士商先正達農作物保護股份公司 | 殺微生物之吡唑衍生物 |
| PY2403614A (es) | 2023-01-27 | 2025-09-11 | Syngenta Crop Protection Ag | Derivados de pirazol microbiocidas |
| AR131665A1 (es) | 2023-02-01 | 2025-04-16 | Syngenta Crop Protection Ag | Composiciones fungicidas |
| EP4455142A1 (en) | 2023-04-26 | 2024-10-30 | Scenic Immunology B.V. | Novel inhibitor of qpctl and/or qc |
| PY2447478A (es) | 2023-06-14 | 2025-03-18 | Syngenta Crop Protection Ag | Composiciones fungicidas |
| WO2025114167A1 (en) | 2023-11-28 | 2025-06-05 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025163143A1 (en) | 2024-02-02 | 2025-08-07 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025191053A1 (en) | 2024-03-14 | 2025-09-18 | Syngenta Crop Protection Ag | Microbiocidal pyrazole derivatives |
| WO2025224308A1 (en) * | 2024-04-25 | 2025-10-30 | Scenic Immunology B.V. | Qpctl inhibitors |
| WO2026022173A1 (en) | 2024-07-26 | 2026-01-29 | Syngenta Crop Protection Ag | Microbiocidal pyrazole compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102186475B (zh) * | 2008-09-04 | 2016-08-03 | 前体生物药物股份公司 | 新抑制剂 |
| US8975417B2 (en) * | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| MX2015016421A (es) * | 2013-05-28 | 2016-03-03 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. |
| KR102084185B1 (ko) * | 2013-08-29 | 2020-03-04 | 주식회사 대웅제약 | 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법 |
| EP3747438A1 (en) * | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
-
2020
- 2020-07-10 MX MX2022000521A patent/MX2022000521A/es unknown
- 2020-07-10 CA CA3147154A patent/CA3147154A1/en active Pending
- 2020-07-10 PH PH1/2022/550079A patent/PH12022550079A1/en unknown
- 2020-07-10 EP EP20743091.9A patent/EP3997091A1/en active Pending
- 2020-07-10 AU AU2020312647A patent/AU2020312647A1/en not_active Abandoned
- 2020-07-10 US US17/626,614 patent/US20230077723A1/en not_active Abandoned
- 2020-07-10 BR BR112022000505A patent/BR112022000505A8/pt unknown
- 2020-07-10 KR KR1020227004600A patent/KR20220054293A/ko not_active Ceased
- 2020-07-10 JP JP2022501167A patent/JP2022542540A/ja active Pending
- 2020-07-10 WO PCT/EP2020/069630 patent/WO2021009068A1/en not_active Ceased
- 2020-07-10 CN CN202080056962.2A patent/CN114466849B/zh active Active
-
2022
- 2022-01-12 IL IL289784A patent/IL289784A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230077723A1 (en) | 2023-03-16 |
| JP2022542540A (ja) | 2022-10-05 |
| PH12022550079A1 (en) | 2023-04-12 |
| CN114466849A (zh) | 2022-05-10 |
| IL289784A (en) | 2022-03-01 |
| BR112022000505A2 (pt) | 2022-03-22 |
| BR112022000505A8 (pt) | 2022-04-12 |
| CA3147154A1 (en) | 2021-01-21 |
| WO2021009068A1 (en) | 2021-01-21 |
| KR20220054293A (ko) | 2022-05-02 |
| EP3997091A1 (en) | 2022-05-18 |
| AU2020312647A1 (en) | 2022-02-24 |
| CN114466849B (zh) | 2024-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022550079A1 (en) | N-substituted-3,4-(fused 5-ring)-5-phenyl-pyrrolidine-2-one compounds as inhibitors of isoqc and/or qc enzyme | |
| MX2022015812A (es) | Inhibidores de cisteina proteasas y sus metodos de uso. | |
| ZA202403923B (en) | Heterocyclic compounds as immunomodulators | |
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| MX2023012981A (es) | Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos. | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| AU2013311573A8 (en) | Methods of treating Alzheimer's disease and pharmaceutical compositions thereof | |
| PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| PH12017500829A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
| PH12018501920B1 (en) | Bromodomain inhibitors | |
| CR20200263A (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5 | |
| MD20140082A2 (ro) | Inhibitor al kinazei inductoare de apoptoză | |
| MX2020012034A (es) | Inhibidores de furina. | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| EA201691447A1 (ru) | 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера | |
| MX2014003408A (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][ 1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la beta-secretasa 1 (bace1). | |
| MY162167A (en) | Substituted acetyl-coa carboxylase inhibitors | |
| MX2017006447A (es) | Agentes antifungicos. | |
| PH12015502365B1 (en) | Bace1 inhibitors | |
| PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
| MX2021007425A (es) | Derivados heterociclicos como bloqueadores de nav1.7 y nav1.8. | |
| NZ702254A (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| PH12019501642A1 (en) | Novel compounds and their use in the treatment of schistosomiasis | |
| MY197595A (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| PH12020500204A1 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease |